NICE decision could limit future development of CAR T therapies;
With its hepatitis C franchise tumbling, Gilead plots knockoffs of its own drugs
Morgan Stanley Global Healthcare Conference Update: Celgene, Merck and Gilead
CAR-T Therapies in 2018
Gilead News: Arthritis Drug, Precision BioSci Deal and Chief Medical Officer Change
Licensing Deals: Biohaven and AstraZeneca, Roivant and Patara, Gilead and Trianni
A Summary of 2017 Trial Initiations in NAFLD
Novartis announced that its BYL719 (alpelisib) met the primary endpoint of progression-free survival (PFS) in its Phase III SOLAR-1 trial. The drug is an alpha-specific PI3K inhibitor, a category of cancer drugs that has a troubling history of adverse events. The SOLAR-1 trial studied BYL719 in combination with fulvestrant compared to fulvestrant alone in postmenopausal women and … Συνεχίστε να διαβάζετε Novartis’s Breast Cancer Drug Looks Promising in Phase III Trial, Despite Category’s Troubling History.
By many standards, and certainly by the way the media covers it and industry promotes it, immuno-oncology therapies using CAR-T are revolutionizing cancer treatments. But what if, as the saying goes, they threw a revolution and nobody came? Or more precisely, what if they threw a revolution and no one was willing to pay for … Συνεχίστε να διαβάζετε Does CAR-T Therapy Have a Payment Problem?.
Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million. Under the terms of the deal, Sierra is paying Gilead an upfront fee of $3 million. There are various potential milestone payments that could reach up to $195 million. The companies indicate that most of the milestones are commercial ones, rather than … Συνεχίστε να διαβάζετε Sierra Oncology Acquires Gilead’s Momelotinib in $198 Million Deal.